Northington Partners has recently completed a capital raise for HoneyLab, a pharmanatural company developing products for skin conditions, pain and nutrition. The capital was raised from Quayside Holdings, the Bay of Plenty Regional Council’s investment arm. The Quayside investment will provide HoneyLab with the resources needed to accelerate the large pipeline of products currently undergoing research and development. HoneyLab is well advanced in discussions with global consumer healthcare pharmaceutical companies on licensing its patented technology. The Company’s existing products are in demand after a series of strongly positive clinical trials which have shown them to be effective for conditions including acne, rosacea and cold sores. Following completion of the capital raising process, Quayside now holds a significant minority position in HoneyLab.